Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial

Federica Riccardo,1 Lidia Tarone,1 Mariateresa Camerino,2 Davide Giacobino,2 Selina Iussich,2 Giuseppina Barutello,1 Maddalena Arigoni,1 Laura Conti,1,2 Elisabetta Bolli,1 Elena Quaglini,1 Irene Fiore Merighi,1 Emanuela Morello,2 Alfredo Dentini,3 Soldano Ferrone,4,5 Paolo Buracco,2,6 Federica Cavallo1

Abstract

Background Melanoma is the most lethal form of skin cancer in humans. Conventional therapies have limited efficacy, and overall response is still unsatisfactory considering that immune checkpoint inhibitors induce lasting clinical responses only in a low percentage of patients. This has prompted us to develop a vaccination strategy employing the tumor antigen chondroitin sulfate proteoglycan (CSPG4) as a target.

Methods To overcome the host’s unresponsiveness to the self-antigen CSPG4, we have taken advantage of the conservation of CSPG4 sequence through phylogenetic evolution, so we have used a vaccine, based on a chimeric DNA molecule encompassing both human (Hu) and dog (Do) portions of CSPG4 (HuDo-CSPG4). We have tested its safety and immunogenicity (primary objectives), along with its therapeutic efficacy (secondary outcome), in a prospective, non-randomized, veterinary clinical trial enrolling 80 client-owned dogs with surgically resected, CSPG4-positive, stage II–IV oral melanoma.

Results Vaccinated dogs developed anti-Do-CSPG4 and Hu-CSPG4 immune response. Interestingly, the antibody titer in vaccinated dogs was significantly associated with the overall survival. Our data suggest that there may be a contribution of the HuDo-CSPG4 vaccination to the improvement of survival of vaccinated dogs as compared with controls treated with conventional therapies alone.

Conclusions HuDo-CSPG4 adjuvant vaccination was safe and immunogenic in dogs with oral melanoma, with potential beneficial effects on the course of the disease. Thanks to the power of naturally occurring canine tumors as predictive models for cancer immunotherapy response, these data may represent a basis for the translation of this approach to the treatment of human patients with CSPG4-positive melanoma subtypes.

Background

Melanoma in humans is the sixth most common cancer in the world, and its incidence has increased over the past 50 years.1 It can affect multiple anatomical sites, defining four major subtypes, each one with distinct clinical characteristics: cutaneous melanoma, arising in non-glabrous skin; acral melanoma, that originates in glabrous skin of the palms, soles and nail beds; mucosal melanoma, which arises from melanocytes in the mucosa; and uveal melanoma, which develops from melanocytes in the uveal tract of the eye.2 Major progress has been recently made mainly in the treatment of cutaneous melanoma thanks to the introduction of BRAF/MEK-targeted3 and immune checkpoint inhibitor (ICIs)-based therapies.4,5 These treatments have induced impressive clinical responses in 20%–50% of patients with melanoma, nevertheless, a still high proportion of patients does not benefit clinically from these therapies.4,5 The other melanoma subtypes, including non-ultraviolet (UV)-induced cutaneous, mucosal and uveal melanomas, are rare and less characterized clinical entities with few therapeutic options and a very poor prognosis.6,8

Tumor antigen (TA)-based vaccination strategies, able to stimulate a long-lasting antitumor immune response, could represent an effective therapeutic option for patients with melanoma. In our study, the TA used as a target is the membrane bound chondroitin sulfate proteoglycan (CSPG4), which is a member of the CSPG family. Members of this family are key bioactive molecules that play a major role in tumor growth, migration, and neoangiogenesis.9,10-12 CSPG4 is an attractive target for antitumor vaccination, since it is highly expressed on melanoma cells in a high percentage of patients with limited inter-lesion and intra-lesion heterogeneity, independently of tumor stage and subtypes, with a restricted expression in normal tissues.11,12 However, CSPG4 is a non-mutated self-antigen, and as such it is poorly immunogenic.11,15
In previous studies, anti-idiotypic monoclonal antibodies (mAbs) which mimic CSPG4 have been shown to be able to overcome a host’s unresponsiveness to this self TA in patients with melanoma and to induce CSPG4-specific antibodies. This humoral immunity appears to have clinical relevance, since it was associated with patients’ survival prolongation. In spite of these encouraging results, the anti-idiotypic mAb approach was abandoned, since the assumed lack of a cellular immune response was thought to be a major deficiency of this type of immunotherapy.16

Guided by these results, we have taken advantage of the high degree of conservation through phylogenetic evolution of CSPG4 sequence to develop an antigen mimicry DNA-based vaccination strategy. Specifically, we have generated and tested a hybrid plasmid encoding a chimeric CSPG4 protein, partially derived from the human (Hu) and partially from the dog (Do) CSPG4 sequence (HuDo-CSPG4). We have previously demonstrated that plasmids coding for chimeric proteins that include both xenogeneic and autologous domains of the target antigen delivered by in vivo electroporation can elicit a humoral and a cellular immune response.17–19

To test the validity of our strategy we have treated dogs affected by spontaneous oral melanoma, since they represent a clinically relevant model of human non-UV-induced and ‘triple wild-type’ cutaneous, mucosal and uveal melanomas.20–22 Canine oral melanoma shares the same aggressive behavior as its human counterpart, with a high propensity to metastasize to lymph nodes and lungs, and has comparable treatment options and clinical responses.22–24 Moreover, dogs affected by oral melanoma have been widely used in immunotherapy trials25 and led to the US Department of Agriculture (USDA)-approval of the DNA vaccine ONCEPT (Merial), carrying the sequence of the human tyrosinase, for the treatment of this canine tumor.26 Importantly, a high percentage of oral canine melanomas express the CSPG4 antigen.27 Therefore, our goals were the evaluation of the safety, immunogenicity, and antitumor potential of HuDo-CSPG4 vaccination in the adjuvant setting, in a prospective, multicentric, phase I, non-randomized, veterinary clinical trial enrolling 80 client-owned dogs affected by spontaneous, CSPG4-positive, stage II–IV, oral melanoma, after the surgical removal of the tumor. HuDo-CSPG4 vaccination, used in association with in vivo electroporation in 52 out of 80 dogs, was found to be well tolerated and immunogenic. The improvement in the overall survival of vaccinated dogs as compared with controls suggests a potential clinical benefit of adjuvant HuDo-CSPG4 vaccination for the treatment of patients affected by malignant melanoma.

METHODS

Cell lines and reagents

The canine CMM-12 and OLGA cells were derived from a primary oral melanoma28 and from a metastatic lymph node,11 respectively; the human skin melanoma SK-MEL-28 cells were purchased from the American Type Culture Collection. Cells were cultured in Dulbecco’s Modified Eagle Medium supplemented with 20% fetal bovine serum (FBS, Sigma-Aldrich) and penicillin/streptomycin (both from Sigma-Aldrich) and maintained at 37°C in a 5% CO2 atmosphere. Cell lines were routinely checked for contamination by mycoplasma using the Mycoalert Detection Kit (Lonza). CSPG4 expression by cell lines was assessed as described29–31 utilizing western blotting, flow cytometric analysis and immunofluorescence of cells stained with a pool of the mAbs TP32, TP49 and VF20-VT87.41, which recognize distinct and spatially distant CSPG4 epitopes.

Generation of the hybrid human/dog (HuDo)-CSPG4 plasmid

The hybrid HuDo-CSPG4 plasmid (pCDNA3.1 backbone) was generated as described.30 Briefly, the first 3737 bp of the Hu-CSPG4 sequence (Gene ID: 1464)26 were ligated to the last 3187 bp of the Do-CSPG4 sequence (Gene ID: 487658). The hybrid HuDo-CSPG4 complementary DNA was then cloned into the pCDNA3.1 plasmid and verified by sequencing (BMR Genomics). The large-scale preparation of the plasmids was carried out with EndoFree Plasmid Giga kits (Qiagen) according to Good Laboratory Practice. The hybrid HuDo-CSPG4 plasmid encodes for a chimeric protein which includes at the N-terminal portion the domain 1 and part of the domain 2 (aa 1–1245) of the Hu-CSPG4 protein and part of domain 2 and the full domain 3 (aa 1246–2307) of the Do-CSPG4 protein at the C-terminal.

Dog enrollment and vaccination

Eighty client-owned dogs were enrolled following owners’ informed consent during the period October 1, 2016 to June 30, 2021. The study protocol was approved by the Italian Ministry of Health (0015537-28/06/2017-DGS AF-MDS-P) and conducted at the Veterinary Teaching Hospital, University of Turin, Grugliasco (Turin), Italy, and the Tyrus Veterinary Clinic, Terni, Italy. Dogs without concurrent life-threatening diseases and with stage II (2–4 cm diameter, negative lymph nodes (LN)), III (>1 cm diameter and negative LN or any tumor size with ipsilateral-positive LN) and IV (any tumor size, with bilateral positive LN without distant metastasis), surgically resected CSPG4-positive oral melanomas, were included in the study. Preoperatively, full tumor staging, defined according to the tumor, node, metastases staging system by Owen,22 included a skull and three-view chest radiography and abdominal ultrasound examination and/or a total body CT. Tumor samples were immunohistochemically tested for CSPG4 expression as previously described.29,33 Briefly, a total score ranging from 0 to 8 was assigned to each melanoma sample considering the value assigned to the proportion of CSPG4 positively stained tumor cells (score from 0 to 5) and the average staining intensity of CSPG4-positive tumor cells (score from 0 to 5).
3). Only dogs bearing an oral melanoma with a CSPG4 score ≥3 were enrolled in the study.

Dogs included in the vaccination arm were adjuvantly immunized with the HuDo-CSPG4 plasmid as previously described, starting 2 weeks after surgery. Briefly, 500 µg of HuDo-CSPG4 plasmid per dog, diluted in 200 µL of 0.03% NaCl solution, were injected into the muscle of the caudal thigh. Two minutes after plasmid injection, nine electric pulses (1 high voltage, amplitude 450 V, length 50 µs, frequency 3 Hz; 1s pause; eight low-voltage amplitude 110 V, length 20 ms, pause 300 ms) were applied to the injection site using the CLINIPORATOR (Igea). Immunization was repeated after 2 weeks and then monthly, for a minimum of 4 and a maximum of 24 cycles. Clinical examinations, three-view chest radiographs and/or CT were performed before each vaccination, as well as sera and peripheral blood mononuclear cells (PBMC) were collected, whenever possible. The Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events V1.1, (VCOG-CTCAE) was used to classify the adverse events.

**Antibody binding assays**

ELISA was performed as previously described. Briefly, 96-well plates (Costar, Sigma-Aldrich) were coated overnight at 4°C with the recombinant D2 (Do–D2) and D3 (Do–D3) domains of the Do-CSPG4 protein (obtained from Genscript), and of the commercially available D3 (Hu-D3) domain of the Hu-CSPG4 protein (R&D Systems) (50 ng/well). Plates were then sequentially incubated with diluted canine sera (1:100) for 2 hours at 37°C and horseradish peroxidase-conjugated anti-dog IgG or IgA xenoantibodies (1:10000; both from R&D system). Plates were washed and chromogenic 3,3',5,5'-tetramethylbenzidine (Sigma-Aldrich) substrate was added. The reaction was stopped by the addition of 2N hydrochloric acid and absorbance was measured at 450 nm on a 680XR microplate reader (Bio-Rad). Vaccinated dogs were considered responders when the fold change between the O.D. at 450 nm of the post-vaccination/pre-vaccination sera was >1.1. Avidity of anti-CSPG4 antibodies produced by vaccinated dogs was tested in a chaotropic ELISA as previously described.

For flow cytometric analysis, CMM-12 and SK-MEL-28 melanoma cells were incubated for 30 min at 4°C with canine sera diluted 1:40 in phosphate-buffered saline (PBS; Sigma-Aldrich). Total IgG and IgA binding was evaluated as previously described. Samples were acquired using a BD FACSVerse (BD BioScience) and analyzed with FlowJO V.10.5.3. Immunofluorescence staining was performed as described using 1×10^5 CMM-12 and SK-MEL-28 cells seeded onto glass coverslips. Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich) at room temperature (RT) and blocked with PBS supplemented with 1% bovine serum albumin (Sigma-Aldrich) and 0.1% Tween-20 (Sigma-Aldrich). For internalization analysis, CMM-12 cells were seeded for 3 hours at RT onto glass coverslips that had been previously coated with fibronectin (5 µg/mL) (Sigma-Aldrich). Cells were then incubated with canine sera (1:10) for 1 hour at 37°C, permeabilized with 0.5% saponin (Fluka), blocked for 1 hour at RT and incubated overnight at 4°C with a pool of the CSPG4-specific mAbs TP32, TP49, VF20-VT87.41 (1:40). Specific antibody binding was revealed with a goat anti-mouse IgG antibody (Alexa Fluor 568; Thermo Fisher Scientific). Nuclei were stained with 4',6-diamidino-2-phenylindole, coverslips were air-dried and mounted.

**Cytofluorimetric analysis of circulating leukocytes**

Thawed PBMC were incubated with human IgG to block the Fc receptor and then stained with the following mAbs: rat anti-dog CD5-fluorescein isothiocyanate (FITC), rat anti-dog CD11b, rat anti-dog CD8-Pacific Blue, mouse anti-dog B cells-Alexa Fluor 647, purified mouse anti-dog CD11b, rat anti-dog major histocompatibility complex (MHC) II-FITC and mouse anti-human CD14-Alexa Fluor 647 (all from AbD Serotec). To reveal CD11b positivity a secondary PE-conjugated anti-mouse IgG (DakoCytomation) was used. Samples were acquired using a BD FACSVerse (BD BioScience) and analyzed with FlowJO V.10.5.3.

**Cytotoxicity assay**

CMM-12 target cells (1×10⁴) were labeled with 2 µM of carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes) and then cultured with thawed PBMC at the effector:target ratio (E:T) of 50:1 for 48 hours at 37°C in a 5% CO₂ atmosphere. PBMC were from 19 dogs of the vaccination arm, selected based on sample accessibility. Antibody-dependent cell-mediated cytotoxicity (ADCC) was performed by incubating PBMC with CMM-12 cells at the E:T ratio of 50:1 overnight at 37°C in a 5% CO₂ atmosphere in the presence of a 1:50 dilution of canine sera collected before and after the vaccination cycles. After staining with 1 µg/mL 7-Amino-ActinomycinD (7-AAD, BD BioSciences), cells were acquired using a BD FACSVerse and analyzed using FlowJO V.10.5.3. Percentage of killing was obtained by back-gating on the CFSE⁻ targets and measuring the percentage of 7-AAD⁺ dead cells, as previously described. Briefly, percentage of specific lysis was calculated with the formula ((dead targets in sample (%) – spontaneously dead targets (%)) /
(dead target maximum (%) − spontaneously dead targets (%)) × 100. Spontaneous death was obtained by culturing target cells without PBMC, whereas maximal death was obtained after treatment with 1% saponin.

**Western blotting**

Western blotting for CSPG4 detection was performed as previously described. The β-Actin (Santa Cruz Biotechnology) and Vinculin (Cell Signaling) were used as protein-loading controls.

**Cell migration assay**

CMM-12 (2×10⁴) cells were incubated with pooled sera (1:10 dilution) from vaccinated dogs for 1 hour at 37°C in a 5% CO₂ atmosphere and then seeded into the top chamber of a 24-transwell plate (8μm pore size; Corning). Migration assay was performed as previously described.

**Statistical analysis**

Shapiro-Wilk or Kolmogorov Smirnoff test were used to evaluate normal distribution. The non-parametric Mann-Whitney test was used when the distribution was not normal. Two-tailed unpaired and paired Student’s t-tests were used to perform the statistical analyses for normally distributed data. The Kaplan-Meier method was used to estimate overall survival and disease-free interval (DFI) of dogs enrolled in the study. Differences in survival times were analyzed using the log-rank test. Pearson’s correlation method was used to estimate the correlation between the antibody response determined by ELISA and survival. Statistical significance was evaluated using GraphPad V.9 software (GraphPad) and values of p<0.05 were considered significant.

**RESULTS**

**Molecular and antigenic profile of the HuDo-CSPG4 plasmid used as a vaccine**

The hybrid HuDo-CSPG4 plasmid includes the N-terminal portion of the Hu-CSPG4 and the C-terminal portion of the Do-CSPG4 sequences (online supplemental figure S1A). The predicted chimeric HuDo-CSPG4 aa sequence (online supplemental figure S1B) has 89.0% identity with the full Hu-CSPG4 sequence and 93.0% with the full Do-CSPG4 sequence. National Institute of Health (NIH)/3T3 fibroblasts transfected with the HuDo-CSPG4 plasmid demonstrated the presence of the two CSPG4 components with the molecular weight of 250kDa and >450kDa (online supplemental figure S1C) as revealed by western blotting using a pool of three mAbs (the TP32, TP49 and VTF20-VT87.41), recognizing distinct Hu-CSPG4 epitopes. Moreover, using this mAb pool, a specific binding on NIH/3T3 fibroblasts transfected with HuDo-CSPG4 was also revealed by flow cytometry analysis (online supplemental figure S1D) and immunofluorescence (online supplemental figure S1E). Overall, these results confirm that the chimeric protein is correctly coded by the hybrid construct and expressed on the cell membrane.

In addition, sera from C57BL/6 mice vaccinated with the HuDo-CSPG4 plasmid stained murine B16 melanoma cells stably overexpressing either the Hu-CSPG4 (B16-Hu-CSPG4; online supplemental figure S2A) or the Do-CSPG4 (B16-Do-CSPG4; online supplemental figure S2B) proteins. Lastly, a significant delay of the tumor incidence was observed in HuDo-CSPG4 vaccinated mice challenged subcutaneously with either B16-Hu-CSPG4 (online supplemental figure S2C) or B16-Do-CSPG4 (online supplemental figure S2D) cells. These results are compatible with the preservation of the antigenic and immunogenic properties of both the Hu-CSPG4 and the Do-CSPG4 domains encoded by the hybrid construct.

**Phase I veterinary clinical trial: eligibility criteria and patient enrollment**

Eighty client-owned dogs with oral melanoma were prospectively enrolled in the study. Their principal characteristics are summarized in (online supplemental table S1). All dogs were treated with an en-bloc resection of the primary tumor, with the inclusion, if feasible, of at least 2 cm of macroscopically normal tissue around the tumor, and regional lymphadenectomy. In some cases (10% of vaccinated dogs and 3.6% of controls), adjuvant radiotherapy was given in addition to surgery. Tumor samples were immunohistochemically tested for CSPG4 expression (n=80) (online supplemental table S1), Ki67 expression (n=78), mitotic index (n=80) and nuclear atypia (n=70) (online supplemental table S2). Dogs were then assigned to the adjuvant vaccination treatment group or the control one according to the owner’s decision. The clinical stage distribution and the CSPG4 expression score were similar in the two arms (online supplemental table S1–S3).

**HuDo-CSPG4 vaccination is safe and with potential beneficial effects on the overall survival of canine melanoma patients**

HuDo-CSPG4 vaccination was started 2 weeks after surgery, repeated 14 days later and then monthly in 52 out of the 80 dogs enrolled in the study (vaccination arm) (figure 1A and online supplemental figure S3). The remaining 28 dogs that did not receive the adjuvant HuDo-CSPG4 vaccination were included in the control arm (online supplemental figure S3).

No significant changes in blood counts, body weight and temperature were detected, as well as no allergic/immunologic events were recorded throughout the entire course of the study. Sixteen out of the 22 dogs with a body weight below 15 kg exhibited transient hind/limb limping after electroporation lasting from some hours to days (grade 1 toxicity, according to the VCOG-CTCAE). No hospitalization was required for any dog. Adjuvantly vaccinated dogs exhibited significantly longer overall survival than the control population treated with conventional therapies alone (log-rank test,
Figure 1  Adjuvant chimeric HuDo-CSPG4 vaccination improves the survival of canine patients affected by CSPG4-positive oral melanomas. (A) Immunization protocol (upper panel) and study design (lower panel). (B) Kaplan-Meier curves comparing the overall survival (in days) of HuDo-CSPG4 vaccinated (blue line) and unvaccinated (gray line) dogs, after the local control of CSPG4-positive oral melanoma, updated to December 2021. Log-rank test, *p=0.0320. (C) Swimmer plot depicting the overall survival of canine melanoma patients enrolled in the study. Briefly, the survival (in days) of dogs with surgically resected CSPG4-positive melanoma, either vaccinated (Vax) or non-vaccinated (Ctrl), is reported, considering the day 0 as the moment of the surgery for each dog. Arrows indicate that the patients were still alive at the time of publication (continued response). For each patient, the moment of recurrence or metastasis detection, if any has been indicated. Black dots indicate patients who died because of unrelated reasons, while red triangles indicate patients who died because of melanoma. Dogs lost in the follow-up (n=3) were also indicated. The median survival time (310 days) for the control group has been indicated by a dotted vertical line. CSPG4, chondroitin sulfate proteoglycan 4; PBMC, peripheral blood mononuclear cells.
Although, it must be noted the reduction of the CSPG4 dogs and the DFI (online supplemental figure S4A, B); between an increased IgG antibody level in responder at the end of the study and 1 (4%) was lost to follow-up and 12 (30%) both.

6 Riccardo F, et al. J Immunother Cancer 2022;10:e004007. doi:10.1136/jitc-2021-004007

D3 responders (figure 2D,E) and a reliable trend for Do–D3 increase from 44% after the fourth vaccination (figure 2B) to 51% (online supplemental figure S5B) and from 46% (figure 2G) to 55% (online supplemental figure S5D), respectively. A significant progressive increase in the antibody levels to the Do–D2 was observed after repeated vaccinations (figure 2C).

Noteworthy, when sera from non-responder dogs were tested against the Do–D2 domain using a chaotropic ELISA, a higher percentage of IgG remained bound to the plate in 70% of the post-vaccination as compared with pre-vaccination sera analyzed (online supplemental figure S6A, B). This increased IgG avidity in the post-vaccination sera suggests that HuDo-CSPG4 vaccination can improve the spontaneous anti-CSPG4 antibody response detectable before vaccination in some of the dogs affected by CSPG4-positive melanoma. However, it must be noted that the spontaneous antibody response to both the Do–D2 and Do–D3 is not predictive of a better patient’s survival (online supplemental figure S6C-H), either considering the entire canine population (online supplemental figure S6D, G) or only dogs who were responders (figure 2) to HuDo-CSPG4 vaccination (online supplemental figure S6E, H).

In view of the clinical risk of recurrence in the oral mucosa following local tumor control, we evaluated whether HuDo-CSPG4 vaccination could also induce anti-CSPG4 IgA antibodies. About 36% and 46% of vaccinated dogs developed an IgA response against the Do–D2 (online supplemental figure S7A, B) and Do–D3 (online supplemental figure S7E, F), respectively. In 71% of responder dogs, we observed the development of a local recurrence as compared with 76% in the non-responder group to the Do–D2; while 66% of dogs who respond to the Do–D3 developed a local recurrence as compared with 81% of non-responder dogs. Moreover, a positive trend between an increased antibody level and a prolonged DFI, considering the local recurrences, was found for the responder dogs to Do–D2 (online supplemental figure S7C, D), but not for those to Do–D3 (online supplemental figure S7G, H).

Table 1 Survival times for canine melanoma patients calculated up to December 31, 2021

| Groups                 | MST (days) | Survival (months) |
|-----------------------|------------|-------------------|
|                        |            | 6   | 12   | 18   | 24   |
| HuDo-CSPG4 (n = 52)   | 653        | 96.15% | 69.23% | 50.00% | 37.25% |
| Control (n = 28)      | 310        | 71.43% | 39.29% | 32.14% | 21.43% |

CSPG4, chondroitin sulfate proteoglycan 4; Do, dog; Hu, human; MST, median survival time.

*p=0.0320) with a median survival time (MST) of 653 and 310 days in the vaccinated and the control group, respectively (figure 1B and C and table 1).

At the end of the observation period (1575 days), 7 out of the 52 (13%) vaccinated dogs were still alive, of which 5 (71%) without evidence of recurrence nor metastasis developed during the study, while in the remaining 2 (29%) dogs we observed the regression of metastasis, and both are currently in remission. Forty-three out of the 52 (83%) vaccinated dogs died during the study and 2 dogs (4%) were lost to follow-up on day 512 and 962, respectively; the latter dog developed both a local recurrence and metastasis on day 214 and 276, respectively. Of the 43 dead dogs, 27 (63%) died because of melanoma and the remaining 16 (37%) succumbed to cancer-unrelated events. In the study period, 40 out of 52 (77%) vaccinated dogs experienced progressive disease; 15 of them (37%) developed local recurrence, 13 (33%) distant metastasis and 12 (30%) both.

In the control arm, 27 out of 28 dogs (96%) were dead at the end of the study and 1 (4%) was lost to follow-up on day 1371, with no recurrence and metastasis developed during the observation period. Out of the 27 deceased dogs, 20 (74%) died because of melanoma and 7 (26%) because of cancer-unrelated events. During the study period 22 out of the 28 (79%) dogs experienced progressive disease; 6 of them (27%) developed local recurrence, 13 (59%) distant metastasis and 3 (14%) both.

**HuDo-CSPG4 is immunogenic in canine melanoma patients**

**Antibody response**

Sera collected from HuDo-CSPG4 vaccinated dogs after the fourth immunization were tested in an ELISA to investigate the ability of the HuDo-CSPG4 vaccine to induce an antibody response against the Do-CSPG4 protein. An increased IgG binding to the recombinant Do–D2 and the Do–D3 domains in the post-vaccination as compared with pre-immunization sera was observed in 44% (figure 2A-C) and 46% (figure 2F-H) of dogs, respectively. Interestingly, in the responder dogs, a correlation between an increased IgG binding and the overall survival was observed, with statistical significance for Do–D2 responders (figure 2D,E) and a reliable trend for Do–D3 responders (figure 2I,J). Only a trend was observed between an increased IgG antibody level in responder dogs and the DFI (online supplemental figure S4A, B); although, it must be noted the reduction of the CSPG4 antigen in recurrences for most dogs (online supplemental figure S4C).

When samples were available, the anti-Do–D2 and anti-Do–D3 antibody response was measured also after the fifth and the sixth immunizations (online supplemental figure S5A, C). The percentage of responder dogs to the Do–D2 and the Do–D3 increase from 44% after the fourth vaccination (figure 2B) to 51% (online supplemental figure S5B) and from 46% (figure 2G) to 55% (online supplemental figure S5D), respectively. A significant progressive increase in the antibody levels to the Do–D2 was observed after repeated vaccinations (figure 2C).
HuDo-CSPG4 vaccination is effective in inducing a specific anti-canine CSPG4 antibody response in dogs. (A) and (F) Analysis of the presence of IgG antibodies against the Do–D2 (A) and Do–D3 (F) domains of the canine CSPG4 protein in the sera of dogs before the first immunization (Pre-Vax, dotted black line) and after the fourth HuDo-CSPG4 vaccination (Post-Vax, blue bars), measured by ELISA. Results are expressed as the ratio (fold change) between the absorbance measured at 450 nm of the Post-Vax and the Pre-Vax sera. Each bar represents a canine patient. (B) and (G) Histograms representing the percentage of responders (blue) and non-responders (black) calculated by enumerating dogs in which sera collected after the fourth immunization displayed an increased ability to bind the Do–D2 (B) and the Do–D3 (G) domains as compared with sera collected before the first immunization. (C) and (H) Violin graphs representing the absorbance measured at 450 nm by ELISA against the Do–D2 (C) and Do–D3 (H) of pre-vaccination and post-vaccination sera from dogs who respond after the fourth, the fifth or the sixth immunizations. Student’s t-test, p*=0.0108, p**<0.0085. (D) and (I) Correlation between the absorbance values measured at 450 nm by ELISA of responder dogs against the Do–D2 (D) and Do–D3 (I) domains and the overall survival. Each dot represents a responder dog. Pearson correlation coefficients (r) are shown. (E) and (J) Kaplan-Meier curves correlating the overall survival of vaccinated dogs who develop (responders) a specific IgG response against the Do–D2 (E) and Do–D3 (J) domains with a high (continuous blue lines) or low (dotted blue lines) antibody level measured in their post-vaccination sera by ELISA, considering as cut-off the mean of the absorbance at 450 nm. Log-rank test, *p=0.0120. CSPG4, chondroitin sulfate proteoglycan 4; Do, dog; Hu, human.
Interestingly, sera collected from HuDo-CSPG4 vaccinated dogs after the fourth immunization exhibited an increased ability to stain canine CMM-12 cells, expressing the Do-CSPG4 protein in its natural conformation (online supplemental figure S8A, B), as compared with sera collected before the first vaccination (figure 3A). In 62% of the vaccinated dogs, post-vaccination sera showed a higher binding to CMM-12 cells as compared with the corresponding pre-vaccination sera (figure 3B). The increased binding of post-vaccination sera was validated by testing them with canine CMM-12 cells in immunofluorescence (figure 3C). An increased binding of vaccine-induced IgA to the canine CMM-12 cells was also found in post-vaccination sera (figure 3D).

Moreover, in 33% (online supplemental figure S9A-D) and 51% (online supplemental figure S9E-G) of HuDo-CSPG4 immunized dogs, vaccine-induced IgG and IgA, respectively, bind also the recombinant human CSPG4 D3 domain (Hu-D3), and the detection of this antibody response is associated with an improved survival (online supplemental figure S9C, D, G). An increased binding of post-vaccination sera compared with pre-vaccination sera was observed also using the human SK-MEL-28 melanoma cells as targets (figure 3E), naturally overexpressing the Hu-CSPG4 antigen (online supplemental figure S8A, B). Specifically, in 82% of HuDo-CSPG4 vaccinated dogs, post-vaccination sera displayed a higher ability to bind SK-MEL-28 cells as compared with those from the same patients before the vaccination cycle (figure 3E,F). The binding of the sera from HuDo-CSPG4 vaccinated dogs was also confirmed by testing them with SK-MEL-28 cells in immunofluorescence (figure 3G).

**Cellular response**

An increase in the percentage of both B and CD4+ T cells was observed in the peripheral blood of 63% and 53%, respectively, of the 19 analyzed dogs following the fourth HuDo-CSPG4 vaccination, as compared with that in the peripheral blood collected before the first immunization (figure 4A). Moreover, in 53% of the analyzed dogs, PBMC collected after the fourth vaccination displayed an increased percentage of CD8+ T cells (figure 4A), and when co-cultured with CMM-12 cells, they were significantly effective in killing CSPG4-positive tumor cells, as compared with those collected before vaccination (figure 4B). Vaccinated dogs that developed an increased cytotoxicity against CSPG4-positive melanoma cells (responders) displayed a longer, despite not significant, overall survival as compared with those that did not (figure 4C), with a MST of 972 days for responders as compared with 594 days for non-responder dogs. A slight increase of the DFI in responder dogs was also observed (figure 4D). Lastly, a decrease (fold change Post-Vax/Pre-Vax <1.0) in the percentage of myeloid derived suppressor cells (MDSC) was observed between the pre-vaccination and corresponding post-vaccination samples in 68% of the vaccinated dogs analyzed (figure 4A).

**Mechanisms underlying the role of HuDo-CSPG4-vaccine-induced antibodies**

The vaccine-induced IgG antibodies recognizing Do-CSPG4 may mediate melanoma cell elimination through an ADCC mechanism. Indeed, in 36% of the sera tested, vaccination-induced antibodies effectively mediated the killing of canine CMM-12 cells (figure 5A). In addition, post-vaccination sera induced Do-CSPG4 internalization (figure 5B) and downregulation (figure 5C), and significantly reduced the proliferative (figure 5D) and migratory (figure 5E) ability of CMM-12 cells. Post-vaccination sera were also able to inhibit the proliferation (figure 6A, left panel) of the canine melanoma cell line OLGA, naturally expressing low levels of CSPG4 (online supplemental figure S8A, B). Interestingly, no inhibition (figure 6A, right panel) was detected when OLGA cells were incubated with dog sera collected after the fourth vaccination with a fully xenogeneic Hu-CSPG4 vaccine, used in previous trials.29,33 This difference may reflect the induction of a higher avidity antibody response by HuDo-CSPG4 as compared with HuCSPG4 vaccination, as demonstrated by a chaotropic ELISA against the Dog-D2 (figure 6B).

These data are supported by the clinical observation that HuDo-CSPG4 vaccination is equally effective for the treatment of melanomas with a low (<5) or high (>5) CSPG4 score (figure 6C), while the antitumor efficacy of Hu-CSPG4 vaccine, was higher for the treatment of melanomas with a CSPG4 score ≥5, weakening its efficacy against oral melanoma with lower CSPG4 positivity.33 These results emphasize the benefit of using the chimeric HuDo-CSPG4 vaccine over the fully Hu-CSPG4.

**DISCUSSION**

The CSPG4 antigen is an appealing comparative immunotherapeutic target, highly expressed on melanoma cells in primary and metastatic lesions in both humans and dogs, with a pivotal role for cancer cell malignancy.11 However, being a self, non-mutated tumor associated antigen (TAA), CSPG4 is poorly immunogenic in both species. To overcome this limitation, we revisited the antigen mimicry concept.

Unlike other vaccines based on the use of xenogeneic TAs as a strategy to break immune-tolerance against a self-antigen,18 including ONCEPT41–43 and our Hu-CSPG4 DNA vaccine,29,33 we developed a chimeric CSPG4 DNA vaccine, HuDo-CSPG4, resulting from the fusion of the cell membrane proximal portion of the dog CSPG4 with the cell membrane distal portion of the human CSPG4, taking advantage of the high homology between human and canine CSPG4 sequences. We evaluated, as primary objectives, the safety and the immunogenicity and, as a secondary outcome, the antitumor potential of HuDo-CSPG4 vaccination in a prospective, non-randomized, veterinary clinical trial, enrolling 80 client-owned dogs affected by locally controlled oral, CSPG4-positive, stage II–IV melanoma. Dogs affected by a CSPG4-negative...
Figure 3  HuDo-CSPG4 vaccine-induced antibodies bind CSPG4-overexpressing canine and human melanoma cells. (A) and (E) Flow cytometry analysis of naturally CSPG4-expressing canine CMM-12 (A) and human SK-MEL-28 (E) melanoma cells incubated with sera from canine patients before the first immunization (Pre-Vax, dotted black line) and after the fourth HuDo-CSPG4 vaccination (Post-Vax, blue bars). Total IgG binding was evaluated using a FITC-conjugated goat anti-dog IgG secondary antibody. Results are expressed as the ratio (fold change) between the percentages (%) of stained cells incubated with the Post-Vax and the Pre-Vax sera. Each bar represents a canine patient. (B) and (F) Histograms representing the percentage of responders (blue) and non-responders (black) calculated by enumerating dogs in which sera collected after the fourth immunization displayed an increased ability (ratio >1.1) to stain the CMM-12 (B) and the SK-MEL-28 (F) melanoma cells as compared with sera collected before the first immunization. (C) and (G) Representative immunofluorescence images (one out of three independent experiments) of canine CMM-12 (C) and human SK-MEL-28 (G) cells stained with Pre-Vax and Post-Vax sera from HuDo-CSPG4 vaccinated dogs. Bound antibodies were revealed using a FITC rabbit anti-dog IgG secondary antibody and nuclei were stained with DAPI. (D) IgA specific binding of Pre-Vax and Post-Vax sera collected from HuDo-CSPG4 vaccinated dogs on canine CMM-12 cells. Results are expressed as the ratio (fold change) between the serum binding potential (sbp) of the Post-Vax and the Pre-Vax sera. CSPG4, chondroitin sulfate proteoglycan 4; DAPI, diamidino-2-phenylindole; Do, dog; Hu, human; FITC, fluorescein isothiocyanate.
Figure 4  HuDo-CSPG4 vaccination is effective in inducing an anti-CSPG4 cellular immune response in dogs. (A) Flow cytometry analysis of the frequency of circulating B cells, CD4+ and CD8+ T cells, and MDSC collected from canine melanoma patients before (Pre-Vax) and after the fourth HuDo-CSPG4 vaccination (Post-Vax). Graphs show the percentage of CD21+ B cells (gated on live cells), of CD4+ and CD8+ T cells (gated on CD5+ cells) and of MHC-II–CD14 – (gated on CD11b+ cells) cells. The numbers of dogs in which a difference in the frequency (fold change >1.1 or fold change <1.1) of a cell population was observed comparing Pre-Vax and Post-Vax PBMC are indicated above in each graph. Student’s t-test, *p=0.0151. (B) Cytotoxic assays to quantify the ability of Pre-Vax and Post-Vax PBMC to kill CSPG4-positive CMM-12 cells. Representative dot plots of one dog analyzed, showing the percentage of 7-AAD+ dead cells among CFSE+ cells (upper panels) are shown. Results are shown as the fold change between the percentage of CMM-12 cells lysed after incubation with Post-Vax and Pre-Vax PBMC for each dog analyzed (lower, left panel, Student’s t-test, *p=0.0260), and as the percentage of dogs of which PBMC induced an increased CMM-12 cell lysis (responders) or not (non responders) (lower, right panel). (C) and (D) Kaplan-Meier curves comparing the overall survival (C) and the disease-free-interval (DFI, D), in days, of vaccinated dogs who develop (responders, continuous blue line) or not (non responders, dotted blue line) a cytotoxic response against the canine CMM-12 cell line. The median survival times (MST) in days for each group has been reported in the overall survival graph. Log-rank test, p=0.2819.

7-AAD, 7-Amino-ActinomycinD; CSPG4, chondroitin sulfate proteoglycan 4; Do, dog; Hu, human; MDSC, myeloid derived suppressor cells; PBMC, peripheral blood mononuclear cells; FITC, fluorescein isothiocyanate; MHC, major histocompatibility complex; CFSE, carboxyfluorescein succinimimidester.
**Figure 5** Potential mechanisms of action of HuDo-CSPG4 vaccine-induced antibodies. (A) Cytotoxic assay to quantify the ability of Pre-Vax and Post-Vax sera to induce the killing (ADCC) of CSPG4-positive CMM-12 cells. Representative dot plots of one dog analyzed, showing the percentage of 7-AAD+ dead cells among CFSE+ cells (upper panels) are shown. Results are reported as the fold change between the percentage of CMM-12 cells lysed after incubation with Post-Vax and Pre-Vax sera for each dog analyzed (lower, left panel), and the percentage of dogs whose sera induced an increased CMM-12 cell lysis (responders) or not (non responders) (lower right panel). (B) Representative immunofluorescence images (one out of three independent experiments) of canine CMM-12 cells incubated at 37°C with pooled sera, collected before (Pre-Vax) and after the fourth HuDo-CSPG4 vaccination (Post-Vax). Anti-CSPG4 lgG binding and localization was detected using a Texas red-conjugated anti-mouse IgG and nuclei were stained with DAPI. (C) Representative Western blot analyses (upper panel) of CSPG4 expression in the lysates of CMM-12 melanoma cells incubated at 37°C for 48 hours with pooled sera collected before (Pre-Vax) and after the fourth HuDo-CSPG4 vaccination (Post-Vax). Relative protein loading was shown using an anti-vinculin antibody. Immunoreactive band density quantification is shown (lower panel); results are reported as relative CSPG4 protein expression, considering Pre-Vax condition as 1. (D) MTT proliferation assay performed on CSPG4-positive canine CMM-12 cells after 48 hours of incubation at 37°C with pool of canine sera collected before (Pre-Vax) or after the fourth HuDo-CSPG4 vaccination (Post-Vax). Results are expressed as the percentage (%) of cell viability, considering Pre-Vax conditions as 100%. Student’s t-test, ****p<0.0001. (E) Migratory ability of canine CMM-12 melanoma cells incubated with pool of canine sera collected before (Pre-Vax) or after the fourth HuDo-CSPG4 vaccination (Post-Vax). Results show the number of migrated cells in four randomly selected fields per well. Student’s t-test, *p=0.0155. 7-AAD, 7-Amino-Actinomycin D; ADCC, antibody-dependent cell-mediated cytotoxicity; CSPG4, chondroitin sulfate proteoglycan 4; DAPI, diamidino-2-phenylindole; Do, dog; Hu, human; FITC, fluorescein isothiocyanate; MTT, 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; CFSE, carboxyfluorescein succinimidyl ester.
Figure 6  HuDo-CSPG4 vaccination induces a high avidity antibody response. (A) MTT proliferation assay performed on a low CSPG4-expressing canine melanoma cell line (OLGA) incubated for 72 hours at 37°C with pool of canine sera collected before (Pre-Vax) or after the fourth HuDo-CSPG4 (blue bars) or Hu-CSPG4 (red bars) vaccination. Results are expressed as percentage (%) of viability, considering Pre-Vax conditions as 100%. Student’s t-test, ****p=0.0002. (B) Avidity of anti-Do–D2 vaccine-induced antibodies in the sera of dogs immunized with either the HuDo-CSPG4 (blue bars) or the (Hu)–CSPG4 (red bars) plasmids, evaluated by a chaotropic ELISA. Results are expressed as percentage (%) of antibodies (Ab) that remain bound after the treatment with the chaotropic agent, as compared with the medium alone considered as 100%. Student’s t-test, **p=0.0050. (C) Kaplan-Meier curves comparing overall survival of HuDo-CSPG4 vaccinated dogs bearing a melanoma with CSPG4-positivity score <5 (dotted blue line) and ≥5 (continuous blue line). CSPG4, chondroitin sulfate proteoglycan 4; Do, dog; Hu, human; MTT, 3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide).
melanoma were not enrolled, since they could not benefit from CSPG4-immune-targeting and display a better prognosis as compared with CSPG4-positive melanoma-affected dogs.29

HuDo-CSPG4 vaccination was effective in inducing an antibody response against the canine CSPG4 protein. After four immunizations, an increased IgG antibody response against both the recombinant D2 and D3 domains of Do-CSPG4 and the native Do-CSPG4 protein was detected in the post-vaccination as compared with pre-vaccination sera in a high percentage of dogs. It must be noted that a spontaneous low affinity anti-CSPG4 antibody response in melanoma-bearing dogs after the local control of the tumor and before vaccination was detected, however this is not predictive for the outcome. This would have resulted in an underestimation of the percentage of responder dogs in our trial. Indeed, spontaneous anticancer autoantibodies are present in patients with a variety of malignancies, including melanoma.12 44 However, in dogs with this spontaneous antibody response we observed the production of antibodies with a higher avidity for CSPG4 after immunization, highlighting the benefit of HuDo-CSPG4 vaccination in improving the quality of the antibody response over the quantity. In addition, for most of the dogs, a further increase in vaccine-induced antibodies was detected following subsequent vaccinations (after the fifth and the sixth immunization cycles). Therefore, we cannot exclude the possibility that, for some dogs, other time points than those that we selected were12 33 would have been more informative as to the development of anti-CSPG4 antibodies, also considering the differences among dogs, including size and age.

However, the finding of a vaccine-induced anti-Do-CSPG4 antibody response is likely to reflect the ability of the antigen mimicry strategy to overcome host’s unresponsiveness to the self-CSPG4, thanks to 86% homology in the aa sequence of the human moiety inside the chimeric HuDo-CSPG4 sequence with its dog counterpart. Under our experimental conditions, the immune clones triggered by the Hu-CSPG4 moiety which cross react with the self-antigen may be amplified by the Do-CSPG4 moiety encoded in the chimeric HuDo-CSPG4. This mechanism may account for the herein observed higher avidity and more marked functional effects of the anti-Do-CSPG4 antibodies elicited by the chimeric HuDo-CSPG4 as compared with those elicited in dogs by immunization with the fully Hu-CSPG4 vaccine, used in a previous pilot veterinary trial.29 33 45

The anti-CSPG4 immune response elicited appears to be clinically relevant in the immunized population, since a significant correlation was observed between the vaccine-induced IgG level of responder dogs and the overall survival. In addition, the induction of a mucosal immunity, potentially relevant for the treatment of oral malignancies, was suggested by the detection of anti-CSPG4 IgA in the serum of a high percentage of the vaccinated dogs. Ultimately, these results allow to speculate that the induction of anti-CSPG4 IgA may be partially protective against local recurrences. Flow cytometry and immunofluorescence analysis demonstrated that vaccine-induced antibodies can bind the Do-CSPG4 antigen over-expressed in its natural conformation on canine CMM-12 melanoma cells, and this is important to assume their effectiveness in mediating antitumor activities in vivo. As suggested by our in vitro results, anti-CSPG4 antibodies that we have detected in the immunized dogs are likely to mediate multiple mechanisms. They include the elimination of melanoma cells by an ADCC mechanism, CSPG4 downregulation, and inhibition of its role in the biology and functional properties of melanoma cells. Such effective anti-CSPG4 antibody response may overcome the ability of melanoma cells to downregulate MHC-I molecules and escape from T cells.46

Finally, an increased percentage of B and CD4+ T cells in the PBMC of vaccinated dogs was observed. A cytotoxic activity of PMBC against canine CMM-12 melanoma cells was found in 11 out of 19 vaccinated dogs analyzed. This response in the immunized population is associated with a better overall survival. Moreover, the reduction in circulating MDSC in the majority of analyzed vaccinees, suggest that, following HuDo-CSPG4 vaccination, the immunosuppression that persists after the local control of the tumor can be, at least partially, reduced.

Based on the evidences of a detectable and effective vaccine-induced immune response, the potential clinical consequences of HuDo-CSPG4 vaccination have been evaluated, considering the overall survival as the most objective measure, for both arms, based on the design of the trial.47

The DFI instead was not considered as a proper clinical endpoint for this study, since it might be affected by the timing and, potentially, by the different imaging diagnostic procedures adopted. Indeed, both X-rays and CT scan were used for diagnosis, but the different methods depended on the improvement of diagnostic techniques over time, and on the owners’ financial resources. While no differences regarding the staging system at baseline were observed between the two arms (ie, vaccinated vs control dogs), in accordance with owners’ decision, unvaccinated dogs underwent only a 3–6-monthly check-up, thus potentially limiting the early detection of local recurrence and metastasis as compared with dogs of the vaccinated arm. This makes the evaluation of the overall survival, rather than the DFI, the sole reasonable endpoint for analysis and comparison with the vaccinated dogs in this study.

The adjuvant HuDo-CSPG4 vaccination envisages a potential benefit on the overall survival of immunized dogs as compared with unvaccinated controls, treated with conventional therapies alone (surgery with or without radiotherapy), prompting its more extensive evaluation in a randomized trial.

Beside these promising results, one evidence which is noteworthy for its clinical application is the lack of limited side effects of vaccination observed in HuDo-CSPG4 vaccinated dogs. These data parallel the lack of

Riccardo F, et al. J Immunother Cancer 2022;10:e004007. doi:10.1136/jitc-2021-004007
toxicity described in human melanoma patients and rats with chemically induced chondrosarcoma immunized with CSPG4 mimics.48–51 These results altogether argue against the broad distribution of CSPG4 in normal tissues reported in the Protein Atlas and support the validity of the studies which have shown that the expression of CSPG4 in normal tissues is restricted to activated peri-
cytes in the tumor microenvironment.12 14 52

Some limitations of this study need to be surmised. As mentioned above, these include the lack of randomization,
with the inherent potential problems of selection
bias and not-blinded outcome evaluation. Unfortunately, a randomization was not possible in this study. In view of the
promising results of our previous veterinary trials, using a
Hu-CSPG4 vaccine for the treatment of canine melanoma
patients, for clinicians it would have been difficult for
ethical reasons to randomly assign patients; concurrently, it
should be noted that the dog owners always refuse to
accept the possibility that their dogs may enter the non-
vaccinated arm. Unlike what is expected in the human
clinics, the veterinary medicine scenario is different and
specifically in this case no dedicated funds covering the
expenses in both vaccinated and non-vaccinated arms of
dogs were available; thus, the non-vaccinated arm was made
up of dogs whose owners were not available to proceed with
further therapies other than surgery. Nevertheless, it
has to be considered that ONCEPT, the first antitumor
vaccine licensed for dogs with locally controlled oral
melanoma, was USDA-approved starting from the results
of similar non-randomized, retrospective studies.49 53
Also, more recent reports on ONCEPT efficacy are non-
randomized, uncontrolled, and retrospective studies.54–56
Other limitations of our study are the use of a single DNA
dose and a single administration procedure as well as the
search of anti-CSPG4 IgA in the serum rather than in the
mucosal compartment. The small number of enrolled
dogs affected by metastatic melanoma is another limita-
tion. Enrollment of other melanoma-bearing dogs with
either local or distant metastasis is warranted to evaluate
the potential benefit of HuDo-CSPG4 vaccination also in
a metastatic setting. Finally, a deeper characterization of
circulating and tumor-infiltrating cells at diagnosis and
after HuDo-CSPG4 vaccination, including T-regulatory
cells, as well as a better dissection of the vaccine-induced
cellular immunity, is needed.

By contrast, the relatively high number of dogs enrolled
in the prospective study, the long-term follow-up, and the
chimeric structure of the proposed HuDo-CSPG4 vaccine
that we showed herein to be effective at breaking toler-
ance to self-CSPG4 in dogs, represent important strengths
of this study.

Nevertheless, since disease progression has been
observed in some vaccinated dogs, possibly also owed
to the escape of CSPG4-negative clones as the result of
antigen loss due to the immunological pressure exerted
by the vaccine, the identification of other key targetable
antigens may be relevant to the design of more effective
and multimodal treatments. In addition, since the
expression of programmed cell death 1 and programmed
death ligand 1 has also been detected in canine melano-
ma patients, combinatorial approaches using ICIs plus
anti-CSPG4 vaccination in this comparative oncology
model should be investigated.57 58

Lastly, it should be noted that no BRAF mutations,
which occur in approximately 50% of human cutaneous
melanomas,3 have been detected in melanoma-bearing
dogs. Still, a significant proportion of human cutaneous
melanoma, as well as almost all uveal and mucosal mel-
nomas, do not show any BRAF alterations but overexpress
CSPG4.52 54

The results from this veterinary trial suggest that the
anti-CSPG4 therapy may represent a new therapeutic
possibility for the treatment of these tumor subtypes
that behave more aggressively and have less favorable
prognosis.

In summary, the application of a novel anti-CSPG4-
mimicry strategy, based on the use of a hybrid DNA
vaccine coding for a human/dog CSPG4 (HuDo-CSPG4)
chimera, resulted safe and immunogenic, displaying a
potential clinical benefit in prolonging the survival of
CSPG4-positive oral melanoma-affected dogs. Ultimately,
thanks to the highly recognized predictive power of
comparative veterinary studies and to the structure of
the vaccine, these findings justify exploring the possi-
bility to translate the chimeric CSPG4 treatment also to
the human clinics. Finally, it should be noted that HuDo-
CSPG4 vaccination could be extended to other CSPG4-
positive cancers in both canine and human patients.

Author affiliations
1Department of Molecular Biotechnology and Health Sciences, University of Turin,
Turin, Italy
2Department of Veterinary Sciences, University of Turin, Turin, Italy
3Clinica Veterinaria Tyrus, Terni, Italy
4Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA

Acknowledgements We thank Dr Marta Gai for technical support with microscope
images and Dr Dale Lawson for his revision and editing of the manuscript.

Contributors FC, PB, and SF conceptualized and administrated the project,
provided funding. FR, LT, DG, and MC designed and performed the experiments
and analyzed the data. SI performed histopathological analysis. GB, MA, EB, and LC
provided technical assistance in performing and analyzing the experiments. PB, AD,
and EM supervised the veterinary trial. IFM produced the vaccine. FC, PB, FR, and
LT wrote the original draft. SF provided reagents and contributed intellectual input.
FC, PB, SF, FR, LT, DG, MC, EQ contributed intellectual input and revised the paper.
FR, FC and PB are the guarantors of the study.

Funding This work was supported by: Italian foundation for cancer research (FR);
Fondazione Umberto Veronesi (FR); Fondazione Ricerca Molinette Onlus Torino, Italy
(FC); Italian Ministry of Health, within the ‘Progetti ordinari di Ricerca Finalizzata’
(grant number RF2013-02359216; PB; FC); National Institutes of Health (grant
number R01DE028172; SF); Faculty resources grant, University of Turin (RILS 2020;
FC); Proof of Concept Instrument Grant, Fondazione Compagnia di San Paolo (POC;
FC).

Competing interests No, there are no competing interests.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the
article or uploaded as supplementary information.

14 Riccardo F, et al. J Immunother Cancer 2022;10:e004007. doi:10.1136/jitc-2021-004007 Open access
Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs
Selina Iussich http://orcid.org/0000-0003-0361-131X
Laura Corti http://orcid.org/0000-0003-1780-098X
Soldano Ferrone http://orcid.org/0000-0003-2960-8834
Paolo Buracco http://orcid.org/0000-0002-0181-0877
Federica Cavallo http://orcid.org/0000-0003-4571-1060

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
2. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 2014;9:339–71.
3. Shaughnessy M, Klebanov N, Tsao H. Clinical and therapeutic implications of melanoma genomics. JTTG 2018:2.
4. Petrova V, Arkhipov I, Weber R. Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. Int J Mol Sci 2020.
5. Kuryk L, Bertinato L, Staniszewska M, et al. From conventional therapies to immunotherapy: melanoma treatment in review. Cancers 2020;12:3057–20.
6. Rabbie R, Ferguson P, Molina-Aguilar C, et al. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol 2019;247:53–59.
7. Kirchoff DD, Deutsch GB, Foshag LJ, et al. Evolving therapeutic strategies in mucosal melanoma have not improved survival over five decades. Am Surg 2018;82:1–5.
8. Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 2018;33:151.
9. Cavallo F, Calogero RA, Forni G. Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 2007;7:707–13.
10. Izzi M, Quaglino E, Amici A, et al. DNA vaccination against oncoantigens: a promise. Oncoimmunology 2012;1:316–25.
11. Rolih V, Barutello G, Iussich S, et al. CSPG4: a prototype oncoantigen for translational immunotherapy studies. J Transl Med 2017;15:151.
12. Nicolosi PA, Dallatamasina A, Perris R. Theranostic impact of NG2/CSPG4 proteoglycan in cancer. Theranostics 2015;5:530–44.
13. Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 2010;109:73–121.
14. Beard RE, Abate-Daga D, Rosati SF, et al. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin Cancer Res 2013;19:4941–50.
15. Träger U, Sierro S, Djordjevic G, et al. The immune response to melanoma is limited by thymic selection of self-antigens. PLoS One 2012;7:e55005.
16. Wang X, Ko EC, Peng L, et al. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Res 2005;65:6976–83.
17. Quaglino E, Mastini C, Amici A, et al. A better immune reaction to ErbB-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res 2010;70:2604–12.
18. Riccardo F, Bolli E, Macagno M, et al. Chimeric DNA vaccines: an effective way to overcome immune tolerance. Curr Top Microbiol Immunol 2017;419:129.
19. Cavallo F, Auriacci L, Mancini R, et al. Xenogeneic vaccination in the therapy of cancer. Expert Opin Biol Ther 2014;14:1427–42.
20. Prouteau A, André C. Canine melanomas as models for human melanomas: clinical, histological, and genetic comparison. Genes 2019;10. doi:10.3390/genes10070501. [Epub ahead of print: 30 06 2019]
21. van der Leyden S, Schott CR, et al. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanina. Nat Commun 2019;10:353.
22. Hernandez B, Adissu HA, Wei B-R, et al. Naturally occurring canine melanoma as a predictive comparative oncology model for human mucosal and other triple wild-type melanomas. Int J Mol Sci 2018;19. doi:10.3390/ijms19020394. [Epub ahead of print: 30 Jan 2018].
23. Tarone L, Barutello G, Iussich S, et al. Naturally occurring cancers in PET dogs as pre-clinical models for cancer immunotherapy. Cancer Immunol Immunother 2018;67:1393–1393.
24. Barutello G, Rolih V, Arigoni M, et al. Strengths and weaknesses of pre-clinical models for human melanoma treatment: Dawn of dogs’ revolution for immunotherapy. Int J Mol Sci 2018;19. doi:10.3390/ijms19030799. [Epub ahead of print: 10 Mar 2018].
25. Almeia RM, Anson A. A review of immunotherapeutic strategies in canine malignant melanoma. Vet Sci 2019;6. doi:10.3390/vetsci6010015. [Epub ahead of print: 12 Feb 2019].
26. Bergman PJ, Clifford CA. Recent advancements in veterinary oncology. Vet Clin North Am Small Anim Pract 2019;49.p. xii–xiv.
27. Mayayo SL, Prestigio S, Maniscalco L, et al. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J 2011;190:e26–e30.
28. Yoshitake R, Saeki K, Watanabe M, et al. Molecular investigation of the anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines: J Vet Med Sci 2013;75:41–45.
29. Riccardo F, Iussich S, Maniscalco L, et al. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res 2014;20:3753–62.
30. Cavallo F, Buracco P, Riccardo F. Nucleic acid molecules encoding for chimeric CSPG4 proteins and therapeutic uses thereof. 2020. Riccardo F, Tarone L, Iussich S. Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma. The AdV Med Oncol. England 2019;11:1–17.
31. Oyen LW, Unit WHOCC, for Comparative Oncology WHOCC. In: Oyen LW. ed. Tnm classification of tumours in domestic Animals/. World Health Organization, 1980; p. VPH/CMO/80.20.
32. Piras LA, Riccardo F, Iussich S, et al. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. Vet Comp Oncol 2017;15:996–1013.
33. LeBlanc AK, Atherton M, Bentley RT, et al. Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE V2) following investigational therapy in dogs and cats. Vet Comp Oncol 2021;19:311–52.
34. Rolih V, Caldeja J, Bolli E, et al. Development of a vl-based vaccine displaying an xct extracellular domain for the treatment of metastatic breast cancer. Cancers 2020;12:1–21.
35. Conti L, Bolli E, Di Lorenzo A, et al. Immunotargeting of the xct cystine/glutamate antiporter: potentiates the efficacy of HER2-targeted immunotherapies in breast cancer. Cancer Immunol Res 2020;8:1039–53.
36. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. J Mol Biol 1990;215:403–10.
37. Imai K, Ng AK, Glassy MC, et al. Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies. J Immunol 1981;127:505–9 http://www.ncbi.nlm.nih.gov/pubmed/6166672
38. Wilson BS, Imai K, Natali PG, et al. Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 1979;28:299–300.
39. Temponi M, Kato T, Forni R, et al. Striatal antigens: homogeneity and diversity of the proteins recognized by antibodies from patients with Parkinson’s disease. Neurology 1989;39:802–10.
40. Bergman PJ, McKnight J, Novosad A. Long-Term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9:1284–90.
41. Grosenbaugh DA, Eald AT, Bergman PJ, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding human melanoma as adjunctive treatment for oral malignant melanoma in dogs.
following surgical excision of the primary tumor. Am J Vet Res 2011;72:1631–8.
43 Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogenic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 2006;24:4582–5.
44 Dummer R, Mittelman A, Fanizzi FP, et al. Non-self-discrimination as a driving concept in the identification of an immunodominant HMW-MAA epitopic peptide sequence by autoantibodies from melanoma cancer patients. Int J Cancer 2004;111:720–6.
45 Giacobino D, Camerino M, Riccardo F, et al. Difference in outcome between curative intent vs marginal excision as a first treatment in dogs with oral malignant melanoma and the impact of adjuvant CSPG4-DNA electrovaccination: a retrospective study on 155 cases. Vet Comp Oncol 2021;19:651–60.
46 Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995;16:487–94.
47 Cheema PK, Burkes RL. Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer. Curr Oncol 2013;20:150–60.
48 Mittelman A, Chen ZJ, Kageshita T, et al. Active specific immunotherapy in patients with melanoma. A clinical trial with mouse anti-idiotype monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest 1990;86:2136–44.
49 Mittelman A, Chen ZJ, Yang H, et al. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotype monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A 1992;89:466–70.
50 Mittelman A, Chen GZ, Wong GY, et al. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotype monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995;1:705–13.
51 Dunn PL, Johnson CA, Styles JM. Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge. Immunology 1987;60:181–6.
52 Rivera Z, Ferrone S, Wang X, et al. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res 2012;18:5352–63.
53 Ottnod JM, Smedley RC, Walshaw R, et al. A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol 2013;11:219–29.
54 Treggiani E, Grant JP, North SM. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. J Vet Med Sci 2016;78:845–50.
55 Turek M, LaDue T, Looper J, et al. Multimodality treatment including ONCEPT for canine oral melanoma: a retrospective analysis of 131 dogs. Vet Radiol Ultrasound 2020;61:471–80.
56 Verganti S, Berlato D, Blackwood L, et al. Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. J Small Anim Pract 2017;58:10–16.
57 Igase M, Nemoto Y, Itamoto K, et al. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep 2020;10:18311.
58 Coy J, Caldwell A, Chow L, et al. PD-1 expression by canine T cells and functional effects of PD-1 blockade. Vet Comp Oncol 2017;15:1487–502.